Janssen, Pharmacyclics submit cancer drug ibrutinib for FDA approval

07/12/2013 | PharmaTimes (U.K.)

Johnson & Johnson's Janssen Biotech and Pharmacyclics have filed an application with the FDA for approval to market their experimental drug ibrutinib for treatment of mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma using data from two midstage studies. Ibrutinib was granted breakthrough therapy designations for three indications by the FDA.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA